The increased longevity of patients with thalassemia and sickle cell disease (SCD) introduces new clinical challenges due to the accumulation of disease-related morbidity, psychosocial issues and health care adjustments. Patients with thalassemia major now live into adulthood without suffering heart failure but must confront delayed puberty, impaired fertility and progressive bone disease. The increased survival in SCD brings to the front previously unrecognized complications including pulmonary hypertension, silent cerebral infarcts and also reproductive dysfunction. Adolescents and young adults (AYAs) have age-related psychosocial needs in their transition from the pediatric health care environment to the adult system. In this review we present the uniquely age-related medical issues facing the AYA thalassemia and SCD cohort in their transition into adulthood.

1.
Borgna-Pignatti C: The life of patients with thalassemia major. Haematologica 2010;95:345-348.
2.
Ladis V, Chouliaras G, Berdoukas V, Chatziliami A, Fragodimitri C, Karabatsos F, Youssef J, Kattamis A, Karagiorga-Lagana M: Survival in a large cohort of Greek patients with transfusion-dependent beta thalassaemia and mortality ratios compared to the general population. Eur J Haematol 2011;86:332-338.
3.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP: Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
4.
Quinn CT, Rogers ZR, Buchanan GR: Survival of children with sickle cell disease. Blood 2004;103:4023-4027.
5.
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ: Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
6.
Rachmilewitz EA, Giardina PJ: How I treat thalassemia. Blood 2011;118:3479-3488.
7.
Borgna-Pignatti C: Modern treatment of thalassaemia intermedia. Br J Haematol 2007;138:291-304.
8.
Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M: Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-1530.
9.
De Sanctis V, Eleftheriou A, Malaventura C: Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004;2(suppl 2):249-255.
10.
Borgna-Pignatti C, Gamberini MR: Complications of thalassemia major and their treatment. Expert Rev Hematol 2011;4:353-366.
11.
Soliman AT, Khalafallah H, Ashour R: Growth and factors affecting it in thalassemia major. Hemoglobin 2009;33(suppl 1):S116-S126.
12.
Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinsky E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, Holm IA, Fleisher M, Grady RW, Peterson CM, Giardina PJ: Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009;146:546-556.
13.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.
14.
Chatterjee R, Bajoria R: Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Ann NY Acad Sci 2010;1202:100-114.
15.
Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti V, et al: Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150-155.
16.
Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H: Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005;74:93-100.
17.
Noetzli LJ, Papudesi J, Coates TD, Wood JC: Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;114:4021-4026.
18.
Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD: Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-1936.
19.
Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S: Predicting pituitary iron and endocrine dysfunction. Ann NY Acad Sci 2010;1202:123-128.
20.
Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V: Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-475.
21.
Singer ST, Vichinsky EP, Gildengorin G, van Disseldorp J, Rosen M, Cedars MI: Reproductive capacity in iron overloaded women with thalassemia major. Blood 2011;118:2878-2881.
22.
Singer ST, Sweeters N, Vega O, Higa A, Vichinsky E, Cedars M: Fertility potential in thalassemia major women: current findings and future diagnostic tools. Ann NY Acad Sci 2010;1202:226-230.
23.
Naik RP, Lanzkron S: Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematol Am Soc Hematol Educ Program 2012, pp 208-214.
24.
Safarinejad MR: Evaluation of semen quality, endocrine profile and hypothalamus-pituitary-testis axis in male patients with homozygous beta-thalassemia major. J Urol 2008;179:2327-2332.
25.
Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J, Cohen A, Neufeld E, Giardina PJ: Prevalence of fractures among the thalassemia syndromes in North America. Bone 2006;38:571-575.
26.
Skordis N, Toumba M: Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. Pediatr Endocrinol Rev 2011;8(suppl 2):300-306.
27.
Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A: Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metab 1998;11(suppl 3):785-790.
28.
Bielinski BK, Darbyshire PJ, Mathers L, Crabtree NJ, Kirk JM, Stirling HF, Shaw NJ: Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 2003;120:353-358.
29.
Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ: Low bone mineral density in adolescents with beta-thalassemia. Ann NY Acad Sci 2005;1054:462-466.
30.
Benigno V, Bertelloni S, Baroncelli GI, Bertacca L, Di Peri S, Cuccia L, Borsellino Z, Maggio MC: Effects of thalassemia major on bone mineral density in late adolescence. J Pediatr Endocrinol Metab 2003;16(suppl 2):337-342.
31.
Terpos E, Voskaridou E: Treatment options for thalassemia patients with osteoporosis. Ann NY Acad Sci 2010;1202:237-243.
32.
Toumba M, Skordis N: Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010;2010:537673.
33.
Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, Skordos G, Christou S: The impact of genotype on endocrine complications in thalassaemia major. Eur J Haematol 2006;77:150-156.
34.
Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, Gasparini P, Siciliani MC, Iolascon A: Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-466.
35.
De Sanctis V: Growth and puberty and its management in thalassaemia. Horm Res 2002;58(suppl 1):72-79.
36.
Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Cappellini MD, Cavagnini F: Growth hormone deficiency (GHD) in adult thalassaemic patients. Clin Endocrinol (Oxf) 2007;67:790-795.
37.
Scacchi M, Danesi L, Cattaneo A, Valassi E, Pecori Giraldi F, Argento C, D'Angelo E, Mirra N, Carnelli V, Zanaboni L, Tampieri B, Cappellini MD, Cavagnini F: Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol (Oxf) 2008;69:202-207.
38.
Fung EB: Nutritional deficiencies in patients with thalassemia. Ann NY Acad Sci 2010;1202:188-196.
39.
Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP: Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet 2012;112:980-990.
40.
Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-336.
41.
Erdogan E, Canatan D, Ormeci AR, Vural H, Aylak F: The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol 2013;27:109-111.
42.
Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P: The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf) 1995;42:279-287.
43.
Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N: Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-575.
44.
Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S: Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major. Pediatr Endocrinol Rev 2008;6(suppl 1): 144-148.
45.
Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, Pringle J, Porter JB: Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 2012;159:462-471.
46.
Forni GL, Perrotta S, Giusti A, Quarta G, Pitrolo L, Cappellini MD, D'Ascola DG, Borgna Pignatti C, Rigano P, Filosa A, Iolascon G, Nobili B, Baldini M, Rosa A, Pinto V, Palummeri E: Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 2012;158:274-282.
47.
Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P: Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. Scientific World Journal 2012;2012:949535.
48.
McGann PT, Nero AC, Ware RE: Current management of sickle cell anemia. Cold Spring Harb Perspect Med 2013;3:a011817.
49.
Quinn CT, Rogers ZR, McCavit TL, Buchanan GR: Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447-3452.
50.
Hamideh D, Alvarez O: Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer 2013;60:1482-1486.
51.
Vij R, Machado RF: Pulmonary complications of hemoglobinopathies. Chest 2010;138:973-983.
52.
Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B: Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease. Blood 1997;89:1787-1792.
53.
Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Manci EA: Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000;342:1855-1865.
54.
Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA: Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996;87:2573-2578.
55.
Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA: Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol 2007;136:343-344.
56.
Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP: Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
57.
Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF: Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;39:112-118.
58.
Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaici A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G: A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44-53.
59.
Colombatti R, Maschietto N, Varotto E, Grison A, Grazzina N, Meneghello L, Teso S, Carli M, Milanesi O, Sainati L: Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol 2010;150:601-609.
60.
Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR: Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 2008;140:104-112.
61.
Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR: Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009;94:340-347.
62.
Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, Coic L, Leveille E, Lemarchand E, Lesprit E, Abadie I, Medejel N, Madhi F, Lemerle S, Biscardi S, Bardakdjian J, Galacteros F, Torres M, Kuentz M, Ferry C, Socie G, Reinert P, Delacourt C: Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011;117:1130-1140, quiz 1436.
63.
DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ: Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012;119:4587-4596.
64.
DeBaun MR, Sarnaik SA, Rodeghier MJ, et al: Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012;119:3684-3690.
65.
Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR: Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology 2001;56:1109-1111.
66.
Dowling MM, Quinn CT, Rogers ZR, Buchanan GR: Acute silent cerebral infarction in children with sickle cell anemia. Pediatr Blood Cancer 2010;54:461-464.
67.
Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR: Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol 2013;70:58-65.
68.
Vichinsky EP, Neumayr LD, Gold JI, Weiner MW, Rule RR, Truran D, Kasten J, Eggleston B, Kesler K, McMahon L, Orringer EP, Harrington T, Kalinyak K, De Castro LM, Kutlar A, Rutherford CJ, Johnson C, Bessman JD, Jordan LB, Armstrong FD: Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 2010;303:1823-1831.
69.
Hijmans CT, Fijnvandraat K, Grootenhuis MA, van Geloven N, Heijboer H, Peters M, Oosterlaan J: Neurocognitive deficits in children with sickle cell disease: a comprehensive profile. Pediatr Blood Cancer 2011;56:783-788.
70.
Berthaut I, Guignedoux G, Kirsch-Noir F, de Larouziere V, Ravel C, Bachir D, Galacteros F, Ancel PY, Kunstmann JM, Levy L, Jouannet P, Girot R, Mandelbaum J: Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008;93:988-993.
71.
Howard J, Oteng-Ntim E: The obstetric management of sickle cell disease. Best Pract Res Clin Obstet Gynaecol 2012;26:25-36.
72.
Villers MS, Jamison MG, De Castro LM, James AH: Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008;199:125.e121-e125.
73.
American Academy of Pediatrics; American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine: A consensus statement on health care transitions for young adults with special health care needs. Pediatrics 2002;110:1304-1306.
74.
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A: Survival and complications in thalassemia. Ann NY Acad Sci 2005;1054:40-47.
75.
Rosen DS, Blum RW, Britto M, Sawyer SM, Siegel DM: Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the society for adolescent medicine. J Adolesc Health 2003;33:309-311.
76.
McPherson M, Thaniel L, Minniti CP: Transition of patients with sickle cell disease from pediatric to adult care: assessing patient readiness. Pediatr Blood Cancer 2009;52:838-841.
77.
Van Staa AL, Jedeloo S, van Meeteren J, Latour JM: Crossing the transition chasm: experiences and recommendations for improving transitional care of young adults, parents and providers. Child Care Health Dev 2011;37:821-832.
78.
Smith GM, Lewis VR, Whitworth E, Gold DT, Thornburg CD: Growing up with sickle cell disease: a pilot study of a transition program for adolescents with sickle cell disease. J Pediatr Hematol Oncol 2011;33:379-382.
79.
Fair CD, Sullivan K, Dizney R, Stackpole A: ‘It's like losing a part of my family': transition expectations of adolescents living with perinatally acquired HIV and their guardians. AIDS Patient Care STDS 2012;26:423-429.
80.
Levine L, Levine M: Health care transition in thalassemia: pediatric to adult-oriented care. Ann NY Acad Sci 2010;1202:244-247.
81.
Jordan L, Swerdlow P, Coates TD: Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol 2013;35:165-169.
82.
Compagno LM: Caring for adults with thalassemia in a pediatric world. Ann NY Acad Sci 2005;1054:266-272.
83.
Bryant R, Young A, Cesario S, Binder B: Transition of chronically ill youth to adult health care: experience of youth with hemoglobinopathy. J Pediatr Health Care 2011;25:275-283.
84.
Musallam K, Cappellini MD, Taher A: Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics 2008;121:e1426-e1429.
85.
Lebensburger JD, Bemrich-Stolz CJ, Howard TH: Barriers in transition from pediatrics to adult medicine in sickle cell anemia. J Blood Med 2012;3:105-112.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.